New incident report
Incident Report Number: 2022-0530
Registrant Reference Number: 2021-CA-000287
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: ONTARIO
PMRA Registration No. PMRA Submission No. EPA Registration No. 2596-168
Product Name: Hartz UltraGuard Dual Action Topical Flea and Tick Prevention for Dogs
Yes
Unknown
Site: Animal / Usage sur un animal domestique
No
Animal's Owner
Dog / Chien
Bulldog
1
Male
0.75
14.97
kg
Skin
Oral
Unknown / Inconnu
>8 hrs <=24 hrs / > 8 h < = 24 h
System
Unknown / Inconnu
Unknown
Unknown
Unknown/Inconnu
Other / Autre
specify Treatment and accidental ingestion
(eg. description of the frequency and severity of the symptoms
On 18-Oct-2021, a 0.75 year old, 14.97 kilogram, intact, male, Bulldog dog, in unknown condition, with no known concomitant medical condition, was administered one dose of Hartz UltraGuard Dual Action Topical Flea and Tick Prevention for Dogs and Puppies 15-30lb (Etofenprox / N-Octyl-Bicycloheptene Dicarboximide (MGK-264) / Piperonyl Butoxide / Pyriproxifen (Nylar)), via the topical route by the animal owner. On 19-Oct-2021 the dog got a hold of the box with the remaining product and ingested an unknown amount of the product (one tube was chewed on and another was missing). This was an extra label use as the product is not intended for consumption. Approximately 8 hours post exposure, the dog exhibited confusion and unspecified abnormal behaviour. Veterinary evaluation was recommended. Approximately 9 hours post exposure, the dog was evaluated by a veterinarian and found to be panting and tachycardic, but mentally appropriate. It is unknown if any treatments were performed. Decontamination and supportive care were discussed with the veterinarian. No further information was received.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.